CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)

被引：6

作者：

Jian, Yuan ^{[1
]}

Zhang, Zhiyao ^{[1
]}

Zhou, Huixing ^{[1
]}

Yang, Guangzhong ^{[1
]}

Geng, Chuanying ^{[1
]}

Wang, Huijuan ^{[1
]}

Gao, Wen ^{[1
]}

Chen, Wenming ^{[1
]}

机构：

[1] Capital Med Univ, Beijing Chaoyang Hosp, Myeloma Res Ctr Beijing, Dept Hematol, Beijing, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

multiple myeloma; CD20; t(11; 14); prognosis; survival; GENETIC ABNORMALITIES; THERAPY; CLASSIFICATION; CONSENSUS; SURVIVAL; CRITERIA; BIOLOGY;

D O I：

10.3389/fonc.2022.1061438

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ObjectiveTranslocation (11;14) is one of the most frequent recurrent cytogenetic abnormalities in multiple myeloma (MM), while its clinical prognostic value remains controversial. CD20 expression is uncommon in MM while strongly associated with t(11;14). This study aimed to investigate whether CD20 could provide further prognostic value in MM patients harboring t(11;14). MethodsCD20 expression detected by flow cytometry was retrospectively analyzed in 211 newly diagnosed MM patients with t(11;14). The clinical characteristics and outcomes were analyzed between CD20 positive and negative patients. ResultsCD20 expression was found in 34.6% (73/211) newly diagnosed MM (NDMM) patients with t(11;14), associated with lower serum creatine levels and lower incidence of plasmacytoma. Based on similar treatment regimens, CD20 positive patients had a comparable overall response rate to CD20 negative patients, whereas had a lower CR/sCR (complete response/stringent complete response) rate than the latter (31.4% vs. 46.4%, P =0.045). Nevertheless, CD20 positive patients had a longer tendency of progression-free survival (PFS) (59.0 vs. 29.0 months, P =0.163) and significantly longer overall survival (OS) (99.0 vs. 56.0 months, P=0.003) than CD20 negative patients. Further investigation among CD20 expression proportion showed that strong expression of CD20 (>80% of bone marrow plasma cells) exhibited the longest OS (median not reached, P =0.011). However, the favorable impact of CD20 expression on survival was eliminated with the contaminant presence of cytogenetic abnormalities besides t(11;14). Autologous stem cell transplantation (ASCT) could improve the prognosis of CD20 negative t(11;14) patients. Multivariate analysis confirmed that CD20 expression was an independent favorable indicator for longer OS in t(11;14) MM patients. ConclusionCD20 expression is a favorable prognostic factor in NDMM with t(11;14) and could provide further risk-stratification value in this heterogeneous disease subgroup.

引用

页数：10

共 50 条

[41] Risk Factors and Prognosis of Extramedullary Disease in Newly-Diagnosed Multiple Myeloma Patients [J].

Gunes, Ebru K. I. L. I. C. ;

Bulduk, Tuba ;

Dumludag, Burak ;

Zengin, Haydar ;

Yildirim, Murat ;

Comert, Melda ;

Ayli, Meltem .

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2024, 34 (04) :175-183

[42] Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma [J].

Binder, M. ;

Rajkumar, S. V. ;

Ketterling, R. P. ;

Greipp, P. T. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Gertz, M. A. ;

Buadi, F. K. ;

Hayman, S. R. ;

Hwa, Y. L. ;

Zeldenrust, S. R. ;

Lust, J. A. ;

Russell, S. J. ;

Leung, N. ;

Kapoor, P. ;

Go, R. S. ;

Gonsalves, W. I. ;

Kyle, R. A. ;

Kumar, S. K. .

BLOOD CANCER JOURNAL, 2017, 7 :e600-e600

[43] Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients [J].

Paiva, B. ;

Gutierrez, N-C ;

Chen, X. ;

Vidriales, M-B ;

Montalban, M-A ;

Rosinol, L. ;

Oriol, A. ;

Martinez-Lopez, J. ;

Mateos, M-V ;

Lopez-Corral, L. ;

Diaz-Rodriguez, E. ;

Perez, J-J ;

Fernandez-Redondo, E. ;

de Arriba, F. ;

Palomera, L. ;

Bengoechea, E. ;

Terol, M-J ;

de Paz, R. ;

Martin, A. ;

Hernandez, J. ;

Orfao, A. ;

Lahuerta, J-J ;

Blade, J. ;

Pandiella, A. ;

San Miguel, J-F .

LEUKEMIA, 2012, 26 (08) :1862-1869

[44] Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients [J].

Chuanying Geng ;

Guangzhong Yang ;

Huixing Zhou ;

Huijuan Wang ;

Yanchen Li ;

Yun Leng ;

Zhiyao Zhang ;

Yuan Jian ;

Wenming Chen .

Clinical and Experimental Medicine, 2023, 23 :2593-2600

[45] What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk? [J].

Gao, Wen ;

Du, Juan ;

Liu, Junru ;

Zhou, Huixing ;

Zhang, Zhiyao ;

Jian, Yuan ;

Yang, Guangzhong ;

Wang, Guorong ;

Tian, Ying ;

Li, Yanchen ;

Wu, Yin ;

Fu, Weijun ;

Li, Juan ;

Chen, Wenming .

FRONTIERS IN ONCOLOGY, 2020, 10

[46] Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma [J].

Pan, Ying ;

Wang, Huiping ;

Tao, Qianshan ;

Zhang, Cui ;

Yang, Dongdong ;

Qin, Hui ;

Xiong, Shudao ;

Tao, Lili ;

Wu, Fan ;

Zhang, Jiakui ;

Zhai, Zhimin .

LEUKEMIA RESEARCH, 2016, 40 :77-82

[47] Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma [J].

Gonsalves, W. I. ;

Rajkumar, S. V. ;

Gupta, V. ;

Morice, W. G. ;

Timm, M. M. ;

Singh, P. P. ;

Dispenzieri, A. ;

Buadi, F. K. ;

Lacy, M. Q. ;

Kapoor, P. ;

Gertz, M. A. ;

Kumar, S. K. .

LEUKEMIA, 2014, 28 (10) :2060-2065

[48] Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM) [J].

Villalba, Ana ;

Pilar Gonzalez-Rodriguez, Ana ;

Arzuaga-Mendez, Javier ;

Puig, Noemi ;

Arnao, Mario ;

Maria Arguinano, Jose ;

Jimenez, Maria ;

Canet, Marta ;

Teruel, Ana, I ;

Sola, Maria ;

Diaz, Francisco J. ;

Encinas, Cristina ;

Garcia, Antonio ;

Rosinol, Laura ;

Suarez, Alexia ;

Sonia Gonzalez, Marta ;

Izquierdo, Isabel ;

Teodoro Hernandez, Miguel ;

Stefania Infante, Maria ;

Jose Sanchez, Maria ;

Sampol, Antonia ;

de la Rubia, Javier .

LEUKEMIA & LYMPHOMA, 2022, 63 (14) :3438-3447

[49] R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study [J].

Chu, Bin ;

Wang, Yu-tong ;

Gao, Shan ;

Shi, Lei ;

Lu, Min-qiu ;

Fang, Li-juan ;

Xiang, Qiu-qing ;

Chen, Yuan ;

Wang, Meng-zhen ;

Wang, Li-fang ;

Sun, Kai ;

Yang, Jing ;

Duan, Fangfang ;

Bao, Li .

ANNALS OF HEMATOLOGY, 2024, 103 (09) :3677-3690

[50] Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment [J].

Shi, Qinglin ;

Wu, Chao ;

Han, Wenmin ;

Zhao, Sishu ;

Wu, Yujie ;

Jin, Yuanyuan ;

Qu, Xiaoyan ;

Li, Jianyong ;

Zhang, Run ;

Chen, Lijuan .

LEUKEMIA & LYMPHOMA, 2021, 62 (03) :709-715

← 1 2 3 4 5 →